Immunic IncIMUX
Price$8.64

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$104.3MTTM through 31 Mar 2026
Free Cash Flow -$81.3MTTM through 31 Mar 2026

Margins

Current

Returns

-69.0%ROE
-55.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.92x
Net Debt-$186.6Mnet cash position
Cash & Equivalents$186.6M

Quality Metrics

Earnings-Beat Rate50.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Development$0
View details

Transitioning towards a commercial-stage organization with NDA submission planned for mid-2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.